Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Apr
22
Today In Oncology
Metastatic NSCLC Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
Methylation-Based AI Model Classifies Tumors of Unknown Origin
Initial Data Shows Safety for WEE1 PKMYT1 Inhibitor Combination in Advanced Solid Tumors
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo